The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine manufacturer located in Kharkov, Ukraine to seek regulatory approval in the country. Biolik will also market and distribute Healive in Ukraine.
The clinical trials are expected to enroll approximately 300 adults and 200 children with dosing and follow-up occurring over a six month period. The companies anticipate that it will take approximately nine to twelve months to complete the trial and receive regulatory approval.
Weidong Yin, chairman, president and CEO of Sinovac, said: “Sinovac is continuing to pursue strategic distribution partnerships that enable us to enter attractive markets outside of China by leveraging our GMP-certified manufacturing capabilities, which are capable of providing low cost, highly scalable production. We look forward to seeing the Ukrainian market contribute to our sales growth.”